background
mannosebind
lectin
collectin
involv
host
defens
infect
whether
mannosebind
lectin
defici
associ
acut
exacerb
chronic
obstruct
pulmonari
diseas
debat
method
particip
studi
design
determin
azithromycin
taken
daili
one
year
decreas
acut
exacerb
serum
mannosebind
lectin
concentr
measur
time
enrol
result
sampl
obtain
subject
trial
preval
mannosebind
lectin
defici
rang
depend
defici
defin
differ
preval
defici
observ
respect
demograph
variabl
assess
differ
observ
time
first
exacerb
rate
exacerb
percentag
subject
requir
hospit
exacerb
defici
versu
without
regardless
defici
defin
conclus
larg
sampl
subject
chronic
obstruct
pulmonari
diseas
select
increas
risk
experienc
acut
exacerb
chronic
obstruct
pulmonari
diseas
mannosebind
lectin
concentr
normal
rang
found
associ
mannosebind
lectin
concentr
time
first
acut
exacerb
frequenc
acut
exacerb
one
year
prospect
followup
mannosebind
lectin
mbl
patternrecognit
collectin
relat
surfact
protein
two
role
host
defens
mbl
activ
complement
via
serin
proteas
particularli
mblassoci
serin
circul
mbl
also
involv
opsonophagocytosi
bind
sever
type
pathogen
phagocyt
via
carbohydr
recognit
domain
trigger
releas
number
proinflammatori
cytokin
facilit
clearanc
apoptot
cell
mbl
secret
primarili
liver
circul
serum
low
mbl
concentr
occur
result
one
three
singl
nucleotid
polymorph
exon
common
caus
defici
caucasian
lxp
haplotyp
result
polymorph
promot
region
gene
present
either
homozyg
mutat
combin
haplotyp
sever
observ
suggest
mbl
defici
may
compromis
host
defens
lung
mbl
bind
carbohydr
surfac
number
respiratori
pathogen
associ
acut
exacerb
chronic
obstruct
pulmonari
diseas
copd
includ
haemophilu
influenza
mycoplasma
pneumonia
influenza
patient
cystic
fibrosi
low
mbl
concentr
decreas
lung
function
increas
preval
burkholderia
cepacia
infect
reduc
surviv
rel
patient
cystic
fibrosi
normal
mbl
concentr
differ
surviv
particularli
notabl
chronic
pseudomona
aeruginosa
infect
homozyg
mutat
gene
low
mbl
concentr
associ
increas
risk
respiratori
infect
immunocompet
subject
increas
frequenc
respiratori
syncyti
viru
infect
wors
outcom
patient
communityacquir
pneumonia
streptococcu
pneumonia
infect
mbl
concentr
bronchoalveolar
lavag
fluid
obtain
small
number
current
former
smoker
copd
lower
fluid
healthi
control
tend
higher
former
smoker
current
smoker
associ
found
genotyp
produc
low
mbl
concentr
preval
copd
howev
studi
assess
associ
low
mbl
concentr
acut
exacerb
copd
aecopd
report
conflict
result
accordingli
prospect
measur
mbl
concentr
larg
cohort
subject
copd
increas
risk
experienc
acut
exacerb
follow
one
year
track
number
acut
exacerb
occur
hypothesi
subject
copd
increas
risk
experienc
aecopd
would
frequent
acut
exacerb
one
year
followup
defici
mbl
subject
men
women
enrol
multicent
random
trial
design
determin
azithromycin
taken
daili
one
year
decreas
frequenc
aecopd
elig
criteria
includ
age
year
clinic
diagnosi
copd
increas
risk
experienc
aecopd
base
criteria
defin
niewoehn
et
al
patient
free
aecopd
minimum
week
prior
enrol
exclus
criteria
includ
diagnosi
asthma
bronchiectasi
among
other
acut
exacerb
defin
complex
respiratori
symptom
increas
new
onset
one
follow
cough
sputum
wheez
dyspnea
chest
tight
durat
least
three
day
requir
treatment
antibiot
system
steroid
serum
collect
time
subject
enrol
studi
experienc
aecopd
minimum
week
store
mbl
concentr
assay
enzymelink
immunosorb
assay
r
system
minneapoli
mn
sampl
dilut
assay
assay
duplic
well
dilut
rang
standard
curv
correspond
concentr
rang
ngml
ngml
concentr
extrapol
n
n
sampl
reassay
either
dilut
new
valu
use
mbl
serum
concentr
one
case
sampl
still
less
detect
limit
dilut
sampl
assign
concentr
less
pgml
mbl
concentr
def
ine
mbl
def
icienc
debat
defin
defici
serum
concentr
ngml
other
def
ine
ngml
still
other
defin
sever
defici
ngml
partial
defici
ngml
ngml
normal
valu
report
manufactur
assay
ngml
rang
ngml
r
system
uncertainti
defin
mbl
defici
four
way
ie
ngml
ngml
ngml
ngml
azithromycin
increas
express
mannos
receptor
uptak
apoptot
cell
human
alveolar
macrophag
decreas
recoveri
apoptot
bronchial
epitheli
cell
accordingli
mbl
concentr
patient
random
receiv
azithromycin
placebo
analyz
separ
togeth
cox
proportionalhazard
model
analysi
use
timetofirstexacerb
outcom
variabl
mbl
group
ie
versu
specifi
limit
primari
variabl
interest
bootstrap
method
use
comput
confid
interv
median
surviv
time
rate
aecopd
determin
divid
number
aecopd
personyear
followup
analyz
function
mbl
concentr
use
neg
binomi
model
mbl
concentr
present
median
interquartil
rang
p
consid
statist
signific
studi
clinicaltrialsgov
number
approv
institut
review
board
particip
center
submit
manuscript
wwwdovepresscom
mbl
assay
perform
baselin
subject
enrol
azithromycin
trial
experienc
one
aecopd
year
prior
enrol
duplic
measur
mbl
coeffici
variat
case
median
mbl
concentr
patient
ngml
interquartil
rang
ngml
inclus
rang
ngml
median
mbl
concentr
subject
random
receiv
azithromycin
placebo
ngml
confid
interv
ci
ngml
ci
respect
p
patient
demograph
clinic
characterist
stratifi
mbl
concentr
summar
tabl
preval
mbl
defici
defici
defin
ngml
respect
tabl
regardless
concentr
mbl
use
defin
mbl
defici
differ
observ
respect
preval
mbl
defici
gender
race
age
except
greater
fraction
women
mbl
defici
defin
ngml
ngml
seen
definit
smoke
statu
chronic
bronchiti
steroid
use
suggest
airflow
limit
wors
gold
global
initi
chronic
obstruct
lung
diseas
stage
higher
subject
mbl
defici
tabl
find
also
observ
subgroup
subject
receiv
azithromycin
placebo
data
shown
analyz
timetofirst
aecopd
use
model
includ
treatment
group
ie
azithromycin
versu
placebo
logtransform
mbl
concentr
stratifi
clinic
treatment
group
signific
p
logtransform
mbl
concentr
p
hazard
ratio
oneunit
increas
logtransform
mbl
concentr
ci
rate
per
personyear
aecopd
negativebinomi
analysi
model
includ
treatment
group
logtransform
mbl
concentr
found
treatment
group
signific
p
logtransform
mbl
concentr
p
coeffici
logtransform
mbl
concentr
model
ci
median
time
first
aecopd
rate
aecopd
per
patientyear
shown
figur
tabl
rel
variou
definit
mbl
defici
five
patient
mbl
concentr
ngml
preclud
life
tabl
analys
patient
subgroup
regardless
mbl
concentr
use
defin
defici
associ
time
first
aecopd
rate
aecopd
mbl
concentr
observ
popul
whole
either
treatment
subgroup
nonsignific
trend
favor
longer
time
first
aecopd
seen
subgroup
subject
mbl
concentr
ng
ml
compar
concentr
ngml
figur
c
differ
observ
mbl
concentr
subject
experienc
one
two
least
three
aecopd
cours
studi
popul
whole
either
treatment
group
tabl
subject
studi
requir
hospit
aecopd
median
mbl
concentr
subject
ci
ngml
azithromycin
placebo
median
mbl
concentr
subject
hospit
p
tabl
import
find
studi
larg
sampl
subject
copd
select
increas
risk
experienc
aecopd
within
one
year
mbl
concentr
normal
rang
report
manufactur
assay
regardless
mbl
concentr
use
defin
mbl
defici
found
associ
defici
time
first
aecopd
rate
aecopd
need
subject
hospit
aecopd
two
studi
conclud
mbl
defici
associ
increas
incid
aecopd
one
conclud
age
spirometri
smoke
histori
subject
three
studi
similar
evalu
except
none
three
studi
select
patient
increas
risk
experienc
acut
exacerb
yang
et
al
found
subject
copd
mbldefici
genotyp
subject
lower
mbl
concentr
wildtyp
genotyp
ngml
iqr
rang
versu
ngml
iqr
rang
p
mbl
concentr
present
fashion
allow
determin
preval
mbl
defici
base
definit
use
literatur
forti
patient
one
admiss
aecopd
twoyear
followup
period
mbldefici
genotyp
fortytwo
patient
aecopd
six
mbldefici
genotyp
odd
ratio
ci
p
determin
mbl
genotyp
genotyp
copd
p
p
respect
associ
mbl
concentr
histori
aecopd
observ
inform
provid
respect
aecopd
defin
eagan
et
al
also
note
subject
gold
stage
diseas
higher
preval
mbl
defici
defin
ngml
found
demograph
copd
sever
indic
less
common
subject
mbl
defici
regardless
defici
defin
tabl
strength
studi
includ
larg
sampl
size
multicent
design
prospect
ascertain
aecopd
use
eventbas
ie
health
care
util
definit
studi
popul
enrich
enrol
subject
anticip
would
increas
submit
manuscript
wwwdovepresscom
risk
experienc
aecopd
within
oneyear
followup
period
base
previou
predictor
identifi
niewoehn
et
al
increas
likelihood
find
higher
preval
mbl
defici
regardless
defici
defin
compar
preval
healthi
control
studi
number
limit
first
measur
mbl
concentr
one
occas
sever
group
demonstr
mbl
acut
phase
reactant
howev
clinic
stabl
patient
mbl
concentr
constant
time
patient
free
aecopd
least
week
meet
inclus
criteria
addit
even
acut
phase
respons
mbl
concentr
patient
low
concentr
increas
reach
normal
valu
accordingli
suggest
low
likelihood
data
confound
spurious
elev
concentr
mbl
result
underestim
preval
mbl
defici
confirm
genotyp
low
mbl
concentr
result
variant
allel
approxim
normal
popul
heterozyg
homozyg
genet
mutat
respect
associ
low
mbl
concentr
although
mbl
concentr
well
correl
genotyp
eg
mbl
concentr
ngml
sensit
specif
variant
polymorph
subject
wildtyp
mbl
gene
may
still
low
concentr
mbl
mbl
concentr
may
vari
much
patient
ident
genotyp
mbl
variant
describ
date
accordingli
assess
relationship
mbl
concentr
aecopd
like
sensit
approach
genotyp
similarli
assess
mbl
function
use
complement
deposit
assay
bouwman
et
al
eisen
suggest
mbl
function
better
way
defin
mbl
defici
determin
mbl
concentr
assess
mbl
concentr
appropri
defin
mbl
defici
studi
seek
associ
infect
differ
mbl
bind
complement
activ
may
vari
depend
method
assess
mbl
concentr
ngml
ngml
associ
decreas
function
saw
associ
mbl
defici
aecopd
mbl
defici
could
still
associ
aecopd
result
infect
one
specif
pathogen
frequenc
specif
pathogen
affect
subject
low
discern
associ
howev
think
possibl
unlik
two
studi
document
associ
mbl
defici
aecopd
found
associ
aecopd
otherwis
defin
caus
potenti
infect
organ
addit
lin
et
al
found
differ
distribut
pathogen
subject
aecopd
without
mbldefici
genotyp
found
subject
mbl
concentr
lower
rang
normal
report
manufactur
assay
exclud
possibl
low
concentr
mbl
associ
aecopd
howev
infrequ
find
impli
even
associ
found
would
pertain
small
minor
patient
suffer
aecopd
conclus
found
low
preval
mbl
defici
subject
increas
risk
experienc
aecopd
associ
mbl
defici
time
first
acut
exacerb
frequenc
acut
exacerb
percent
subject
requir
hospit
acut
exacerb
subject
mbl
defici
regardless
defici
defin
accordingli
data
support
idea
mbl
might
therapeut
target
reduc
incid
aecopd
rather
impli
copd
inflammatori
disord
system
manifest
fundament
pathophysiolog
copd
differ
condit
mbl
defici
seem
clear
risk
factor
ie
childhood
pneumonia
rheumatoid
arthriti
system
lupu
